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The current influenza vaccine provides narrow protection against the strains included in
the vaccine, and needs to be reformulated every few years in response to the constantly
evolving new strains. Novel approaches are directed toward developing vaccines that
provide broader protection by targeting B and T cell epitopes that are conserved between
different strains of the virus. In this paper, we focus on developing mathematical models
to explore the CD8 T cell responses to influenza, how they can be boosted, and the
conditions under which they contribute to protection. Our models suggest that the
interplay between spatial heterogeneity (with the virus infecting the respiratory tract
and the immune response being generated in the secondary lymphoid organs) and
T cell differentiation (with proliferation occurring in the lymphoid organs giving rise to a
subpopulation of resident T cells in the respiratory tract) is the key to understand the
dynamics of protection afforded by the CD8 T cell response to influenza. Our results
suggest that the time lag for the generation of resident T cells in the respiratory tract
and their rate of decay following infection are the key factors that limit the efficacy of CD8
T cell responses. The models predict that an increase in the level of central memory T cells
leads to a gradual decrease in the viral load, and, in contrast, there is a sharper protection
threshold for the relationship between the size of the population of resident T cells and
protection. The models also suggest that repeated natural influenza infections cause the
number of central memory CD8 T cells and the peak number of resident memory CD8
T cells to reach their plateaus, and while the former is maintained, the latter decays with
time since the most recent infection.
Keywords: recall response, influenza, T cell, resident memory, central memory
1. INTRODUCTION
Influenza A is a vaccine preventable disease that still causes substantial morbidity and mortality
(1). Currently approved vaccines aim at boosting antibody responses to major influenza surface
proteins hemagglutinin (HA) and neuraminidase (NA). These antigens constantly mutate resulting
in antigenic drift and requiring annual update to the virus strains in the vaccine. Furthermore, the
current vaccination approach leaves the population almost completely unprotected following much
larger antigenic changes in the influenza virus called antigenic shifts (for example, from H1N1 to
H2N2) that are associated with pandemics (2, 3).
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The major focus of research and vaccination has been on
antibody responses to theHA andNAproteins of influenza, which
exhibit considerable evolution. Experimental studies suggest that
CD8 T cell and antibody responses provide two independent
responses that seem to be redundant to some extent (4–7). In
contrast to epitopes that are targeted by antibody responses, the
CD8 T cell epitopes on the virus are largely conserved between
influenza strains within a given subtype and even between dif-
ferent subtypes (8–11). Thus, CD8 T cell immunity generated
from an infection with one influenza strain might provide some
protection following a challenge with a new strain. This has been
shown in animal model systems following subsequent infections
with two heterosubtypic strains of influenza as well as by adoptive
transfer experiments (12–15). Challenge of an animal that has
recovered from an infection with one influenza strain with a het-
erosubtypic (i.e., shifted) strain allows us to assess the contribution
of T cells to protection because of the lack of cross-reactive anti-
bodies between the influenza viruses of different subtypes. Several
experimental studies have shown that infection of mice with one
strain of influenza can lessen the disease caused by infection with
heterosubtypic strains (12–15). In particular, infection of mice
and non-human primates with seasonal influenza can protect
against challenge with a heterosubtypic pandemic strain (14, 16,
17). A second line of evidence comes from the adoptive transfer
experiments. It has been shown that the adoptive transfer of large
numbers of memory CD8 T cells, generated following H3N2
influenza infection, into naive congenic mice can provide some
protection following infection with a pandemic H1N1 strain (12).
Studies in the animal model systems described above have
clearly shown that T cell-mediated protection is in principle
possible to achieve, and this is supported by human studies.
Retrospective studies have shown that prior infection of humans
with the seasonal H1N1 strain provided some protection to the
pandemic H2N2 strain in 1957 (18). Furthermore, the level of
preexisting influenza-specific cytotoxic T cells was associatedwith
a lack of viral shedding 4–5 days after inoculation of human
volunteers with influenza virus, indicating faster virus clearance,
although there was no clear association with influenza-related
symptoms (19).
In this paper, we use mathematical models to explore how
repeated influenza infections affect the generation of CD8 T cell
immunity, how this immunity wanes with time, and how protec-
tion against recall influenza infections depends on the magnitude
of this immunity. The models consider the key features of the
interplay between the virus and the CD8 T cell response. We
include spatial heterogeneity as the location of the infection in
the respiratory tract is different from the secondary lymphoid
organs where the CD8 T cell response is generated. Further-
more, modeling the dynamics of generation of responses requires
incorporation of the different populations of CD8 T cells and
their migration between the secondary lymphoid organs and the
respiratory tract where the infection is localized.
We specifically use the models to ask the following questions.
First, what determines the dynamics of the virus and the different
subpopulations of CD8 T cells in the lymph nodes and respi-
ratory tract following primary infection? Second, how does the
number of influenza-specific CD8 T cells in the lymph nodes and
respiratory tract decay following the clearance of the infection?
Third, how is protection related to the number of influenza-
specific CD8 T cells in the secondary lymphoid organs and res-
piratory tract? Fourth, what affects the dynamics of virus and
CD8 T cells during recall responses and, in particular, how do
repeated infections boost CD8 T cell immunity and why do
not they generate long-term protection from all new influenza
infections?
2. MATERIALS AND METHODS
2.1. Mathematical Model Formulation
The models consider the key features of the interplay between
the virus and the CD8 T cell response. The basic model is shown
schematically in Figure 1. The immune response to the influenza
virus mainly occurs in the two compartments – the respiratory
tract as the actual site of infection and secondary lymphoid organs,
such as lymph nodes, where the expansion of influenza-specific
CD8 T cells occurs. The model also includes the target cells
(epithelial cells) in which the virus can replicate, the virus, and
the key subpopulations of CD8 T cells in the lymph nodes and
resident cells in the lungs.
We model the dynamics of the virus and innate immunity
along the lines previously described (20–22). Briefly, at the site of
infection, free virus (V) can infect susceptible target epithelial cells
(T), generating infected cells (I), which produce new virus par-
ticles [see equations (1)–(3)]. The term TV represents the rate
of infection of susceptible target cells by free virus. Infected cells
activate innate immunity, which differs from adaptive immunity
in being a saturable response (having maximum scaled to unity).
The rate of activation of innate immunity depends on the number
of infected cells and is half-maximal when I=M [equation (4)].
Innate immunity (via type I interferons) causes uninfected cells
to become refractory to infection (23) at rate kM. Based on earlier
models, we assume that during the timescale of an acute infection,
the production of new target cells can be neglected, and that
refractory state do not revert back to the susceptible state. The
initial number of target cells in an adult’s upper respiratory tract
was previously estimated as 4 108 (20). We assume no death of
target cells on the short scale of influenza infection, but infected
cells have reduced lifespan in comparison to the target cells, and
their lifespan is described by parameter  1 (see Table 1 for other
model parameters).
The T cell proliferation occurs in response to antigen in the sec-
ondary lymphoid organs.We assume that the rate at which antigen
is brought into lymph node by dendritic cells is proportional to
the amount of virus at the site of infection [see Figure 1 and
equation (5)]. The number of influenza-specific CD8 T cells in
the lymph nodes at the onset of infection, TP, includes both naive
and memory T cells, and they are recruited into the population
of proliferating cells, TE, at rate proportional to the amount of
antigen A+A . The TE population grows by clonal expansion in an
antigen-dependentmanner (i.e., at per capita rate  A+A ). Some of
the proliferating T cells migrate to the respiratory tract by sensing
the cytokines generated through activation of innate immunity
M and become resident T cells TR. The TR cells decay at rate dR.
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FIGURE 1 | Schematic of a within-host model of influenza infection. The model variables are target (uninfected) epithelial cells (T ), infected epithelial cells (I),
virus titer (V ), innate immunity (cytokines) (M), antigen presented by dendritic cells (A), and four populations of CD8 T cells such as virus-specific precursor cells (TP),
proliferating cells (TE), central memory cells (TM ), and cells which are resident at the respiratory tract (TR). We do not separately model dendritic cells, instead we
consider them together with antigen as one variable. An immune response to the influenza virus mainly occurs in the two compartments – lining of the respiratory
tract, which is the actual site of infection and secondary lymphoid tissue (lymph nodes) where expansion of virus-specific T cells occurs.
TABLE 1 |Model parameters unless otherwise specified in the figure legend.
Model parameter Symbol Units Value
Virus infectivity  TCID50 ml 1 day 1 310 05
Virus production per cell p TCID50 day 1 0.04
Rate of virus clearance c Day 1 3
Infected-cell lifespan  1 Day 1
Rate of killing of infected cell by TR kR Cells 1 day 1 0.007
Rate of conversion to refractory state kM Cells 1 day 1 4
Max. activation rate for innate M Day 1 1
Number of infected cells for half-max
activation of M
M Cells 1
Decay rate for innate immunity dM Day 1 0.2
Rate of virus conversion to antigen  Day 1 0.3
Rate of antigen decay dA Day 1 1.7
T cell proliferation rate  Day 1 2.15
Antigen for half-maximum  TCID50 ml 1 50
proliferation
Rate of migration to site of infection  Cells 1 day 1 1.2
Rate of conversion TE to TM r Day 1 0.07
Rate of apoptosis for TE  Day 1 0.4
Death rate of TR dR Day 1 0.1
As the antigen is cleared (i.e., at rate proportional to (1  A+A )),
the TE population contracts by apoptosis at per capita rate  and
differentiates into long-lived memory cells TM at per capita rate r.
During recall responses, the preexisting influenza-specific central
memory T cells are incorporated by changing the number of
precursor cells, and we neglect the differences in the recruitment
of naive and memory cells into TE.
With this assumptions, the dynamics of response to influenza
infection can be described by the following differential equations:
(target cells) dTdt =  TV  kMMT (1)
(infected cells) dIdt = TV  kRTRI  I (2)
(viral titer) dVdt = pI  cV (3)
(innate) dMdt =
MI
(M + I)
(1 M)  dMM (4)
(antigen) dAdt = V  dAA (5)
(presursor) dTPdt =  TP

A
+ A

(6)
(expanding) dTEdt = (TP + TE)

A
+ A

  (+ r)TE

1  A
+ A

  TEM
(7)
(memory) dTMdt = rTE

1  A
+ A

(8)
(resident) dTRdt = TEM  dRTR (9)
We focus on immune response to acute infection, which is
different from the response during persistent infections that
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involve very different T cell differentiation mechanisms as has
been shown for CMV infection (24, 25). Our simple model
for the differentiation and migration of CD8 T cells following
influenza infections captures the key features of the response
and is robust to many details of the pathways of T cell
differentiation and to variation in parameters in biologically
reasonable ranges (see Figures S1 and S2 in Supplementary
Material). There are several controversies in the area of T cell
differentiation and lineage relationship of CD8 T cell subsets
(26–29).Ourmodel phenomenologically captures the observation
that following the response, a fraction r+r of the population
at the peak survive as long-lived memory cells, and, conse-
quently, is robust to the details of the underlying differentiation
pathways.
We would like to note that as we focus on the role of CD8
T cells, we consider secondary infection only with heterosub-
typic strain of influenza. In this case antibodies, developed dur-
ing the primary response do not cross-react with the new virus
strain.
3. RESULTS
3.1. Dynamics of Primary Immune
Response
Figure 2 shows the results of our model for the dynamics of
primary immune response to the influenza. The virus undergoes
an expansion phase following a contraction phase. As in previ-
ous modeling studies (20–22), the peak of the virus is largely
controlled by available target cells and innate immunity. T cells
proliferate and a fraction of them migrate to the respiratory tract,
where they kill the virus-infected cells and help to eliminate the
infection. There is a delay in generation of primary CD8 T cell
response due to separate spatial locations of virus entrance and
place where corresponding processed antigen stimulates T cell
proliferation. Proliferating CD8 T cells migrate back to the site
of infection. They reach a sufficient number to affect the virus
dynamics around day 6–7 and augment the innate immune
system-mediated virus control. After virus clearance, expanded
T cells undergo a contraction phase and develop a centralmemory
T cell pool. Proliferation and subsequent contraction of virus-
specific precursor cells in response to primary infection results
in about 2–3 orders of magnitude increase in central memory
T cells (TM). Resident T cells at the site of infection initially
follow the dynamics of expanding cells TE, but have a slower rate
of contraction after the virus clearance. The qualitative features
described above are relatively robust to changes in the parameters
within the biologically reasonable regime chosen (see Figure S1 in
Supplementary Material).
Two T cell populations are left after primary response. Central
memory T cells TM are known to have low level of decay (30),
so we assume no decay rate for them in the model. The decay
rate of resident memory T cells TR is described by parameter
dR in the model. We estimated its value from the data on the
primary influenza A infection in mice (Figure 3A). The decay
rate for resident CD8 T cells at the respiratory tract of humans
is unknown, and in our model, we assume its value to be similar
to the one estimated in mice.
FIGURE 2 | Dynamics of primary immune response to influenza
infection. Model parameters and initial values for model variables are shown
in Tables 1 and 2.
TABLE 2 | Initial values for model variables unless otherwise specified in the
figure legend.
Model variable Symbol Units Initial value
Target (uninfected) epithelial cells T Cells 4108
Infected epithelial cells I Cells 0
Viral titer V TCID50 ml 1 1
Innate immunity M Normalized 10 6
Antigen A TCID50 ml 1 0
Precursor T cells TP Cells 1
Proliferating T cells TE Cells 0
Central memory T cells TM Cells 0
Resident T cells TR Cells 0
These values represent the “naive” state, before first influenza infection encounter. Initial
value for precursor T cells is normalized by the number of virus-specific CD8 T cells and
thus equal to 1.
3.2. Dynamics of Secondary Immune
Response
Figure 3B shows the dynamics of the virus when secondary infec-
tion occurs 1month or 1 year after the primary infection. Several
observations can be made. First, during secondary infection, the
achieved maximum of virus titer is always lower than in primary
infection. Second, the extended time between the infections leads
to less reduction in the level of virus replication in comparison
to primary infection. Third, the duration of secondary infection
is shorter by a couple days in both cases. As our model does not
consider waning of CD8 central memory T cells, the observed
difference in the achieved virus peak values and duration of
infections in Figure 3B is due to a loss of resident memory T cells
between 1month and 1 year after the primary infection.
Next, we dissect, in more detail, the role of central mem-
ory T cells and resident T cells in the dynamics observed in
Figure 3B. Figure 4A shows how the integral viral load changes
when secondary infection occurs at different time intervals after
the primary infection. For the initial conditions at the beginning
of secondary infection, we take the corresponding values of TM
and TR from the same time point of simulations of primary
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FIGURE 3 | (A) shows the dynamics of loss of resident CD8 T cells after primary infection and estimation of the value of parameter dR (the rate of decay of resident
T cells) from the data on mice intranasally infected with primary influenza A virus strain A/HKx31 (H3N2) at 30,000 50% egg infectious dose (EID50). Numbers of lung
resident CD8 T cells specific for influenza epitopes FluNP and FluPA were measured at indicated time points. Each data point is the average from 5 to 20 mice.
All experiments were completed in accordance with the Institutional Animal Care and Use Committee guidelines of Emory University. (B) shows the dynamics of virus
during primary versus recall infections when recall infection happens 30days or 1 year after the first infection. For secondary infections the initial values for TP and TR
were taken from the corresponding values of variables TP+ TM and TR, respectively, in simulation of primary infection with other parameters and initial values as in
Tables 1 and 2.
infection. The brief period of integral viral load value below 10
could be considered as strain-transcending immunity. In this
case, the amount of resident T cells that exhibit cytotoxic activity
at the site of infection is sufficient to prevent the infection. After
the clearance of primary infection, an increase in the time between
primary and secondary infections leads to a decrease in the level of
resident memory T cells at the beginning of secondary infection
and to a corresponding monotonic increase in the integral viral
load until it reaches a plateau level. This plateau is set by the
level of central memory T cells established after primary infection.
Three curves on Figure 4A correspond to the different values
of parameter dR. Equal integral viral load values on three curves
during their raising phases correspond to equal levels of resident
memory T cells at the onset of the corresponding secondary
infections.
3.3. Effect of Additional Requirement
of Activation of Resident T Cells
We also consider the case where resident T cells require time for
activation before they can respond to a secondary virus challenge.
We modified the equations for infected cells (I) and TR accord-
ingly and added an equation for activated resident T cells (TRA):
(infected cells) dIdt = TV  kRTRAI  I (10)
(resident) dTRdt =  dRTR   kactTRV
+ kRMTRA
V
(R + V)
(11)
(activated resident) dTRAdt = TEM+ kactTRV  dRTRA
  kRMTRA V
(R + V)
(12)
Figure 4B shows the model simulations similar to Figure 4A
but adjusted for the case of required activation for resident T cells.
The delay in resident T cell killing activity modifies the integral
viral load if secondary infections occur during second and third
weeks after primary infection leading to an increase in the integral
viral load. The effect of activation is less for the later times of
the introduction of second virus. The gradual loss of protection
with time is still determined by the rate of the decline of the
resident memory T cell population. We would like to note that
the integral viral load curves are mostly affected when secondary
infection occurs 2–3weeks after primary infection, and at these
time points, we expect that resident T cells are still not converted
into memory state. This allows us to conclude that there might be
a brief period of sterilizing immunity immediately after the first
influenza infection due to the resident T cells.Wedefine sterilizing
immunity as a condition with very limited or no virus replication
as seen in Figures 4A and 6B.
3.4. Modulation of Recall Response by
Prior Immunity
Assuming that each infection might boost the memory pool of
CD8T cells, a given individual at different timesmight have differ-
ent levels of prior immunity in both central memory and resident
memory compartments. The exact rules of how preexisting T cells
immunity modulate an immune response to influenza challenge
are unknown.
Figure 5 shows how the integral viral load depends on the level
of central and resident memory CD8 T cells at the onset of recall
infection in our proposed model [equation (1)–(9)]. Relatively,
high level of resident T cells at the site of infection is necessary
to prevent the infection. Value of parameter kR correlates with
the threshold value of TR for sterilizing immunity (see Figure S2
in Supplementary Material). Central memory T cells could not
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FIGURE 4 | Dependance of integral viral load achieved during secondary influenza infection on the time between primary and recall infections.
Different symbols show three different indicated values for the model parameter dR describing the decay of resident T cells at the site of infection. (A) shows the case
when resident memory T cells are able to kill the virus infected cells immediately after the onset of secondary infection. (B) considers the case when resident T cells
require activation to be able to kill virus-infected cells. Corresponding parameters are kact= 0.2 TCID50–1 ml day–1, kRM=0.2, R= 1.
FIGURE 5 | Integral viral load dependence on the number of central
memory and resident memory T cells at the onset of recall infection.
All parameters are as in Figure 2 and Table 1.
prevent the infection but their increase leads to gradual protection
as it reduces the integral viral load.
3.5. Effect of Repeated Influenza Infections
on Boosting of T Cell Responses
The key question is will repeated influenza infections keep
boosting the central memory T cells and the peak of resident
T cells achieved during infection or will these responses satu-
rate? Figure 6A shows the model prediction for the integral viral
load and the established level of central memory T cells after
indicated number of sequential influenza infections. We assume
that the next infection occurs at least 1 year after the previous
one and use established level of central memory T cells from the
previous infection as the initial condition for the new infection.
We assume that the amount of resident T cells is significantly
reduced before the new influenza season. After a few infections,
both TM and integral viral load established their plateau levels.
The balance between the use of existing central memory T cells
and repopulation with newly formed central memory T cells is
achieved.
Our model predicts that the higher level of proliferating cells
during the secondary response leads to the higher level of the
resident T cells. This equates to a longer period of sterilizing
immunity after secondary infection. Figure 6B shows how the
corresponding Figure 4A is modified when we consider the ter-
tiary infection and plot how integral viral load depends on the
time period between the second and the third influenza infections.
This result is robust in a wide range of model parameters and
is a consequence of higher level of central memory T cell at
the beginning of the secondary infection in comparison to the
primary infection.
4. DISCUSSION
In this paper, we used the mathematical models to explore the
role of different memory CD8 T cell populations in protection
against recall influenza infections. To capture the main features
of immune response to influenza a spatial heterogeneity and
migration between two locations were included in the models. In
themodel an infection occurs in the respiratory tract, correspond-
ing processed antigen is delivered to the secondary lymphoid
organs, where it stimulates an expansion of influenza-specific
CD8 T cells with subsequent migration of expanded cells to the
site of infection to kill the virus.We considered specifically the role
of two CD8 T cell populations in protection from recall infections:
centralmemoryT cells that predominantly reside in the secondary
lymphoid organs and resident T cells in the respiratory tract. We
showed that these two distinct populations can give very different
protection mechanisms.
During the primary infection, the main factor determining
the dynamics of CD8 T cell response is spatial heterogeneity.
Antigen needs to be delivered to the secondary lymphoid organs,
and expanded cells migrate back to the site of infection, which
determines the timing of the response. The key factors shaping
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FIGURE 6 | Recall responses to sequential influenza infections. (A) shows how integral viral load and number of central memory T cells (TM) depends on the
number of influenza infections. The initial amount of TM for each infection is taken from the established equilibrium level values after preceding infection. (B) shows
the dependance of integral viral load in tertiary (3°) influenza infection on the time between 2° and 3° infections. The model prediction is shown for three indicated
values of the rate of loss of resident memory T cells (dR).
the dynamics of the recall response are the numbers of central
memory and resident CD8 T cells. The model predicts that large
number of resident T cells in the respiratory tract at the onset of
recall infection may contribute to short-term strain-transcending
immunity (Figure 5). On the contrary, the central memory T cells
in the absence of resident T cells will not prevent the infection.
However, an increase in their level gradually reduces the integral
viral load during recall infection resulting in a quicker recov-
ery. These model predictions are consistent with the data show-
ing that preexisting influenza-specific CD8 T cells reduce virus
titers in the lungs and trachea and protect from lethal challenge
of both homologous and heterologous type A influenza viruses
(12–15, 17).
Our model predicts that the key parameter to predict the
longevity of T cell mediated strain-transcending immunity is the
rate of loss of resident T cells in the respiratory tract. Previously,
it has been shown that tissue-resident memory T cells in mice
are relatively stable for 300–700 days (31–33). Interestingly, unlike
resident T cells in other tissues (for example, skin resident T cells),
the resident T cells in themice respiratory tract show relatively fast
decline. You can see a decrease of about two orders of magnitude
in their numbers during the first month after primary influenza
infection (Figure 3). In the model, we assume one population of
resident memory T cells with single-exponential decay based on
the available mice data.
The model predicts a longer period of strain-transcending
immunity after secondary and further recall infections in compar-
ison to primary infection. It will depend on the two factors: the
level of expansion of T cells during secondary (recall) infection
that determines the maximum of resident T cells achieved during
infection and the further decay rate of these resident T cells.
Currently, there are no mice data for the rate of decline of resi-
dent T cells in the respiratory tract after secondary infection. We
assume that the rate of decline of resident T cells after secondary
and further recall infections is similar to the one measured after
primary infection. In this case, the model predicts that the strain-
transcending immunity provided by resident memory T cells will
last longer after secondary infection, but the duration of this
immunity will hit a plateau level after few infections with no
further increase. This reflects the initial increase with further
plateau level of central memory T cells resulted from sequential
infections (Figure 6).
To provide the true sterilizing immunity, the resident memory
T cells should be able to immediately kill the virus-infected cells
in respiratory tract tissues. This model assumption is supported
by the studies showing that resident memory cells in the lungs are
typically of the effector memory phenotype. They have upregu-
lated CD69 and CD25 surface markers and lack of IL-7R expres-
sion, and might respond quickly to secondary virus challenge
(34–36). We showed that relaxing this assumption and allowing
some time for activation of the resident memory T cells still leads
to a significant reduction in the integral viral load shortly after
infection.
The model predicts that the amount of central memory T cells
stabilizes after few infections. This established level in the absence
of resident memory T cells still leads to a relatively large inte-
gral viral load during a recall infection. This is consistent with
previous estimations that for the most of their lives adults have
an influenza infection every 5 years on average (37). The extent
of waning of T cell immunity is an open question. In the model,
we assume that central memory T cells are maintained without
decay. It has been shown that in the mice, large numbers of virus-
specific memory CD8 T cells circulate through the lymphoid
tissues of the previously infected animals for at least 2 years (30).
The estimation of the longevity of influenza-specific T cells in
humans is complicated by sampling T cells only from the blood
(and not the lymph nodes) and at the current state is controversial
(38, 39).
When we explored the role of resident T cells in protection
(Figures 4 and 6B), we reset the level of innate immunity and
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target cells to their inactivated states at the beginning of a recall
infection.We expect higher level of protection if the innate immu-
nity did not revert to an inactive state or part of the cells in the
respiratory tract is still in refractory or incomplete recovery states.
The more detailed model accessing the role of waning of innate
immunity together with the loss of resident T cells needs to be
further developed.
We did not include antibody responses in our model and
do not consider the role of preexisting antibody in protection
during recall responses. Most of the antibody response dur-
ing primary response to influenza is directed against the head
region on HA. For immune response to the secondary het-
erosubtypic infection, we do not expect significant level of the
cross-reactive antibodies as their main targeted virus proteins,
specifically epitopes on the head region of HA, are substantially
changed. It has been shown that antibodies to the epitopes on
the stem region of HA can be broadly cross-reactive and able
to recognize other subtypes (40–46). Thus, although we might
neglect the contribution from these broadly cross-reactive anti-
bodies to the stem during second infection, the repeated infec-
tions might sufficiently increase their level to facilitate the virus
clearance, changing the extent of expansion of central memory
T cells.
In summary, our model suggests that the resident memory
CD8T cellmight contribute to the short-term strain-transcending
immunity previously proposed by epidemiological studies in
humans (47). In the case of repeated infections, themodel predicts
that the duration of strain-transcending immunity due to the
resident CD8 T cells might increase in comparison to the case of
primary infection and be on the scale of fewmonths. Alternatively,
preexisting antibodies at the beginning of recall infection may
explain the short-term strain-transcending immunity if the rate
of waning of some subsets of B-cell specific immunity is on the
same scale. Both considered populations of CD8 T cells might be
especially beneficial in the case of pandemic influenza in which
there are no preexisting antibodies. The protective effect of central
memory T cells might have a major contribution when the level
of resident memory T cells is low such as at the beginning of an
influenza season.
Current vaccines are not designed to induce influenza-specific
cytotoxic CD8 T cells, but instead lead to boosting of the antibody
responses to HA antigens that undergo drift and shift. Under-
standing the mechanisms underlying T cell-mediated immunity
to influenza might help designing the heterosubtypic vaccines
that are able to protect in the event of an unexpected pandemic
challenge.
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